An observational study in AIDS (Acquired Immunodeficiency Syndrome), Cardiovascular and Cerebrovascular Diseases and Respiratory Comorbidities, sponsored by Hospital Alemão Oswaldo Cruz. Recruiting at 9 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Hospital Alemão Oswaldo Cruz · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Acquired Immunodeficiency Syndrome with a site in Brazil — 7 open to participants now, 10 under way, 4 of them phase 3. Acquired Immunodeficiency Syndrome · Brazil.
Among the 57 studies in Acquired Immunodeficiency Syndrome with a site in Brazil, this one is the 8th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2025, is one of 14 observational ones, and was the 56th registered.
3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →7 of the 57 studies in Acquired Immunodeficiency Syndrome with a site in Brazil are open now. Recruiting first, the newest first:
Federal University of São Paulo · Sites in Brazil
Ages 18–60
Federal University of São Paulo · Sites in Brazil
Ages 18–65
Federal University of Health Science of Porto Alegre · Sites in Brazil
Ages 18+
Code Pharma · Sites in Brazil
Ages 18+
Oswaldo Cruz Foundation · Sites in Brazil
Ages 18–59 · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 743 is above the median of 289 across 504 observational studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 132 across the 42 interventional studies, 923 across the 14 observational. Of the 40 that completed or were terminated, 16 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 57 have an industry lead sponsor. The 10 most frequent:
Hospital Alemão Oswaldo Cruz is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Hospital Alemão Oswaldo Cruz has 1 study filed under Acquired Immunodeficiency Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Acquired Immunodeficiency Syndrome with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07044297Phase 3Merck Sharp & Dohme LLCA Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) | 2027-07-22 |
| NCT07118683Hospital Alemão Oswaldo CruzBRAZILIAN REGISTRY OF CHRONIC NON-COMMUNICABLE DISEASES IN PEOPLE LIVING WITH HIV/AIDS | 2026-11 |
| NCT06805656Federal University of São PauloMulti Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals | 2027-03-01 |
| NCT06497504GlaxoSmithKlineStudy of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) | 2027-04-22 |
| NCT07903441Federal University of São PauloMultiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral Treatment | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 57 studies in Acquired Immunodeficiency Syndrome with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
BRAVO proposes the establishment of a comprehensive registry of chronic noncommunicable diseases (NCDs), providing crucial data for the formulation of effective health policies for people living with HIV/AIDS (PLWHA). BRAVO is a cross-sectional study, that will collect on the study allocation sociodemographic data, risk factors related to the main NCDs, physical examination data and samples for determination of biochemical and metabolic parameters. To this end, the study will include co-participating research centers from the 5 Brazilian geographic macro-regions.
The BRAVO is a multicenter observational study. It includes a cross-sectional baseline assessment to evaluate cardiometabolic health, mental health, and quality of life among people living with HIV/AIDS (PLWHA).
Adults (≥18 years) with a confirmed HIV/AIDS diagnosis from across Brazil will be recruited in 2025 and 2026. Participation requires informed consent. The study captures data on risk factors, diseases, anthropometrics, and biological samples, ART adherence, mental health status, and quality of life (WHOQOL-BREF).
Data are collected using REDCap©, covering: i) Demographics and socioeconomic indicators; ii) Clinical and lab tests (cholesterol, HbA1c, triglycerides); iii) Physical measures (BMI, blood pressure, waist-hip ratio); iv) Respiratory (spirometry), renal, hepatic, and bone assessments (DXA); v) STIs, cancer risk, and CIMT (carotid ultrasound); vi) ART adherence (Morisky-Green), viral load, CD4/CD8 counts; vii) Mental health (depression, anxiety, substance use); and viii) Quality of life via WHOQOL-BREF.
Both validated and project-developed instruments will assess risk factors and outcomes. While validated tools improve reliability, the use of unvalidated questionnaires in certain domains (e.g., interpersonal violence) may introduce bias.
The target sample size is 743 participants, calculated to estimate a 12% prevalence of depression (the condition with the lowest expected prevalence among the non-communicable conditions of interest, derived from a systematic review in low- and middle-income countries) with 20% relative precision and 95% confidence, accounting for 5% refusals or incomplete data.
Statistical Analysis Cross-sectional analysis uses standard tests (Chi-square, t-test, ANOVA, logistic regression) with methods for handling non-normal data and multivariable modeling.
Subgroup analyses are planned for key populations (e.g., transgender, Black individuals, cisgender women).
Challenges No retention strategies are currently outlined, which could affect the study's internal validity due to participant attrition over time. Best practices like reminders and engagement initiatives are recommended.
Ethics The protocol has received approval from the Hospital Alemão Oswaldo Cruz ethics committee (CAAE: 7.003.613). Informed consent and participant confidentiality are ensured.
People living with HIV or Aids.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prevelance of chronic non-communicable diseases and mental disorders
Prevalence of cardiovascular diseases, non-infectious respiratory diseases, chronic kidney disease and cancers, depression, dependence on alcohol and illicit substances, self-harm and physical violence.
Time frame: Baseline
Prevalence of metabolic and behavioral risk factors for chronic non-communicable diseases
History of hypertension, diabetes mellitus, dyslipidemia, smoking, physical activity, use of illicit drugs, alcoholism, dietary risk and continuous use medications, measurement of blood pressure, weight, height, abdominal and hip circumference, CD4, CD8, fasting blood glucose, HbA1C, total cholesterol and fractions, triglycerides, apolipoprotein A and B, serum and urinary creatinine, cystatin-C, urine 1, urinary albumin, serum and urinary phosphorus, urinary macroglobulin, urinary retinol-binding protein, AST, AST, Hepatitis A, B and C serologies, bone densitometry parameters, carotid ultrasound and spirometry.
Time frame: Baseline
Prevalence of participants with good adherence to antiretroviral therapy.
Adherence to antiretroviral therapy will be assessed using the 8-item Morisky-Green tool adapted for patients with HIV/AIDS. The instrument consists of eight dichotomous items. The questions were formulated to avoid a 'yes-saying' bias, so one point is assigned to each 'no' answer, except in item 5, which is reversed. At the end, patients are classified according to the score obtained as low adherers (score \<6), medium adherers (score 6 to \<8) and high adherers (score 8). The original authors also proposed a dichotomous cut-off of low (score \<6) vs. high/medium adherence (score ≥6) to facilitate statistical analysis.
Time frame: Baseline and 1 year after
Profile of Quality of life of participants
Quality of life will be assessed by WHOQOL-BREF. The WHOQOL-BREF, a shortened version of the WHOQOL-100, is a 26-item questionnaire used to assess an individual's quality of life. It categorizes responses into four domains: Physical Health, Psychological Health, Social Relationships, and Environment. Each domain, along with the overall quality of life and general health questions, is scored on a 5-point Likert scale, which is then transformed to a 0-100 scale. A score of 100 represents the best possible quality of life within that domain.
Time frame: Baseline and 1 year after
Not enrolling at this site.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Nov 2026, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome →
Hospital Alemão Oswaldo Cruz